Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Oktober 2018 10:07 ET | Quelle: Silence Therapeutics plc

US Patent Trial & Appeal Board (PTAB) Upholds Silence Patent by Denying First of Five Patent Grant Review Applications Filed by Alnylam

LONDON, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Silence Therapeutics plc, (AIM:SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the...
12. Oktober 2018 10:05 ET | Quelle: Silence Therapeutics plc

Silence Therapeutics Announces Receipt of a New European Notice of Intention to Grant a Patent and the Launch of an Interim European Injunction Application against Onpattro™

LONDON, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Silence Therapeutics plc, (AIM:SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the...
26. September 2018 02:00 ET | Quelle: Silence Therapeutics plc

Silence Therapeutics to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

LONDON, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Silence Therapeutics plc, (AIM:SLN) (“Silence” or “the Company”) a leader in the discovery, delivery, and development of novel RNA therapeutics for the...
07. August 2018 02:00 ET | Quelle: Silence Therapeutics plc

Silence Therapeutics litigation: patisiran EU marketing authorisation imminent

LONDON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Silence Therapeutics plc, (AIM:SLN) (“Silence” or “the Company”) a leader in the discovery and development of novel RNA therapeutics, announces today an...

Vorherige Seite